Five Prime Therapeutics Reaches Analyst Target Price

In recent trading, shares of Five Prime Therapeutics, Inc ( FPRX) have crossed above the average analyst 12-month target price of $56.00, changing hands for $57.76/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher — if things are looking up for the company, perhaps it is time for that target price to be raised.

START SLIDESHOW:
The Top 25 Broker Analyst Picks of the S&P 500 »

There are 3 different analyst targets contributing to that average for Five Prime Therapeutics, Inc, but the average is just that — a mathematical average. There are analysts with lower targets than the average, including one looking for a price of $50.00. And then on the other side of the spectrum one analyst has a target as high as $60.00. The standard deviation is $5.291.

But the whole reason to look at the average FPRX price target in the first place is to tap into a "wisdom of crowds" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with FPRX crossing above that average target price of $56.00/share, investors in FPRX have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $56.00 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? Below is a table showing the current thinking of the analysts that cover Five Prime Therapeutics, Inc:

If you liked this article you might like

Biotech Only Sector in the Red as Trump Vows to Crackdown on Drug Pricing, Biggest Movers

Today Five Prime Therapeutics (FPRX) Hits New Lifetime High

Five Prime Therapeutics (FPRX) Is Today's Strong On High Volume Stock

3 Small Biotechs That Look Very Healthy

3 Small Biotechs That Look Very Healthy

Five Prime Therapeutics (FPRX) Is Today's Perilous Reversal Stock